http://www.fpnotebook.com/
Renal Artery StenosisAka: Renovascular disease, Ischemic Nephropathy
- Epidemiology
- Renal Artery Stenosis is the most common cause of secondary Hypertension (1-5%)
- Responsible for as much as 25% of Hypertension refractory to medications
- Types
- Atherosclerotic Renal Artery Stenosis (90%)
- Fibromuscular Dysplasia (10%): Also associated with ruptured aneurysms and dissections
- Medial fibroplasia (most common FMD type, has string of beads appearance on imaging)
- Perimedial fibroplasia
- Intimal fibroplasia
- Adventitial fibroplasia
- Evaluation: Diagnostic Clues
- Hypertension
- Recent onset of Hypertension
- No Family History of Hypertension
- Hypertension onset under age 30 or over 55 years
- Hypertension with Hypokalemia and Hyponatremia (Hyperaldosterone state)
- Hypertension resistant to therapy
- Increased Blood Pressure on Diuretic
- Excellent response to ACE Inhibitor
- ACE Inhibitor increases Serum Creatinine
- Comorbid vascular disease
- Retinopathy
- Systolic or diastolic abdominal bruit
- Long History of Tobacco use
- Coronary Artery Disease
- Cerebrovascular Disease
- Peripheral Vascular Disease
- Renal dysfunction
- Especially Serum Creatinine rise on ACE Inhibitors
- Recurrent pulmonary edema
- Asymmetric or bilaterally small kidneys
- Labs: Diagnosis (rarely used)
- Plasma renin assay before and after ACE Inhibitor
- Morning Sample
- Unusual to be <3ng/ml/hour in renal vascular disease
- Imaging: Diagnosis
- Renal artery duplex sonography (Preferred test where experienced operators)
- Efficacy
- Operator dependent for accurate results
- Test Sensitivity: 84-98%
- Test Specificity: 62-99% (Better Specificity than MRA)
- Renal resistive index has prognostic value pre-operatively
- RRI<80 predicts best Hypertension improvement with revascularization
- Magnetic Resonance Angiography (MRA)
- Consider preferred Screening Test if sonographer not experienced with RAS screening
- Precaution: Gadolinium-Induced Nephrogenic Systemic Fibrosis (nearly always fatal)
- Consider alternative screening in renal insufficiency (esp. where Serum Creatinine >2.5)
- Efficacy
- Overestimates extrarenal stenosis
- Test Sensitivity: 90-100%
- Test Specificity: 76-94%
- CT Angiography
- Precautions
- Do not use if renal insufficiency due to Intravenous Contrast material
- Significant radiation exposure
- Efficacy
- Test Sensitivity: 89-100%
- Test Specificity: 82-100%
- Arteriogram
- Gold standard but invasive
- Imaging with and without ACE Inhibitor (rarely used now, listed for historical purposes only)
- Renal vein sampling or
- Radionuclide renal scan
- Management: Medical
- Hypertension control
- ACE Inhibitor or Angiotensin Receptor Blocker
- Diuretics (e.g. Chlorthalidone or Hydrochlorothiazide)
- Hyperlipidemia control (goal LDL 70-100)
- Statin AntiHyperlipidemics (e.g. Simvastatin)
- Maximize Diabetes Mellitus management
- Management: Surgical interventions for revascularization
- Indications
- Refractory Hypertension on 3 or more medications including a Diuretic
- Progressive Azotemia
- Acute Renal Failure with ACE Inhibitor (or ARB) with comorbid Congestive Heart Failure
- Recurrent flash pulmonary edema
- Bilateral Renal Artery Stenosis
- Stenosis of solitary kidney
- Renal resistive index <0.80
- Contraindications (Relative): Factors favoring conservative therapy
- Good Hypertension control on 1 or 2 agents
- Normal Renal Function
- Advanced renal atrophy (<7.5 cm)
- Renal resistive index >0.80 (predicts poor Hypertension response to revascularization)
- Significant Proteinuria
- Procedures
- Surgical Revascularization
- Rarely used now unless undergoing concurrent open AAA repair
- Percutaneous transluminal renal Angioplasty
- Stenting has replaced PTRA in most centers due to recoil and recurrent stenosis
- Renal artery stenting (preferred)
- Prognosis: Five year survival in atherosclerotic Renal Artery Stenosis
- Unilateral Renal Artery Stenosis: 96% five year survival
- Bilateral Renal Artery Stenosis: 74% five year survival
- Stenosis or occlusion of solitary kidney: 47% five year survival
- End-stage renal disease on Hemodialysis: 18% five year survival (50% two year survival)
- References
- Shetty (2007) 29th Annual CV Conference, HealthPartners, St. Paul, MN
Navigation Tree